ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021

Your Name: Yin-Ying Ren

Manuscript Title: The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ATM-21-5648

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|
| All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | √ None |
| | |

Time frame: Since the initial planning of the work
|   | Description                                                                                                                                                                                                 | Yes/No  | Value |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                                                                   | ✔️/☐   | -None |
| 3 | Royalties or licenses                                                                                                                                                                                      | ✔️/☐   | -None |
| 4 | Consulting fees                                                                                                                                                                                           | ✔️/☐   | -None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events                                                                                           | ☐/✔️   | -None |
| 6 | Payment for expert testimony                                                                                                                                                                             | ✔️/☐   | -None |
| 7 | Support for attending meetings and/or travel                                                                                                                                                               | ✔️/☐   | -None |
| 8 | Patents planned, issued or pending                                                                                                                                                                         | ✔️/☐   | -None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                                                                                                                          | ☐/✔️   | -None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                                                                                         | ☐/✔️   | -None |
|11 | Stock or stock options                                                                                                                                                                                    | ✔️/☐   | -None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                                                                                                           | ✔️/☐   | -None |
|13 | Other financial or non-financial interests                                                                                                                                                                 | ✔️/☐   | -None |

Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ ___ November 13, 2021 __________________________________________________________________________

Your Name: ___ He-Ting Dong __________________________________________________________________________

Manuscript Title: ___ The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ___ ATM-21-5648 __________________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ___ √ None |
|   | No time limit for this item.                                                                                      |                                                                                 |
|   |                                                                                                                  |                                                                                 |
|   | Time frame: past 36 months                                                                 |
|---|--------------------------------------------------------------------------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                   |
|   | __ √ __ None                                                                               |
| 3 | Royalties or licenses                                                                       |
|   | __ √ __ None                                                                               |
| 4 | Consulting fees                                                                             |
|   | __ √ __ None                                                                               |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |
|   | _ √ ___ None                                                                               |
| 6 | Payment for expert testimony                                                                |
|   | __ √ __ None                                                                               |
| 7 | Support for attending meetings and/or travel                                                 |
|   | __ √ __ None                                                                               |
| 8 | Patents planned, issued or pending                                                          |
|   | __ √ __ None                                                                               |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                           |
|   | _ √ ___ None                                                                               |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |
|   | _ √ ___ None                                                                               |
|11 | Stock or stock options                                                                     |
|   | _ √ ___ None                                                                               |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services           |
|   | __ √ __ None                                                                               |
|13 | Other financial or non-financial interests                                                   |
|   | __ √ __ None                                                                               |

**Please summarize the above conflict of interest in the following box:**

The authors have no conflicts of interest to declare.

**Please place an “X” next to the following statement to indicate your agreement:**

_ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021

Your Name: Jian-Yi Liao

Manuscript Title: The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ATM-21-5648

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| #  | Specifications/Comments (e.g., if payments were made to you or to your institution) | Time frame: Since the initial planning of the work |
|----|----------------------------------------------------------------------------------|-----------------------------------------------|
| 1  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | √ None                                       |
|    | No time limit for this item.                                                     |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|    |                                                                                  |                                               |
|   | Time frame: past 36 months |
|---|---------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | √  None |
| 3 | Royalties or licenses | √  None |
| 4 | Consulting fees | √  None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | √  None |
| 6 | Payment for expert testimony | √  None |
| 7 | Support for attending meetings and/or travel | √  None |
| 8 | Patents planned, issued or pending | √  None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | √  None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | √  None |
| 11 | Stock or stock options | √  None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | √  None |
| 13 | Other financial or non-financial interests | √  None |

Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021

Your Name: Hui-Ming Sun

Manuscript Title: The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ATM-21-5648

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | √ None |
|   | No time limit for this item. | |

Time frame: Since the initial planning of the work
|   | Description                                                                 | Yes | No | None |
|---|----------------------------------------------------------------------------|-----|----|------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).     |     |    | √    |
| 3 | Royalties or licenses                                                        |     |    | √    |
| 4 | Consulting fees                                                             |     |    | √    |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,          |     |    | √    |
|   | manuscript writing or educational events                                     |     |    |      |
| 6 | Payment for expert testimony                                                |     |    | √    |
| 7 | Support for attending meetings and/or travel                                 |     |    | √    |
| 8 | Patents planned, issued or pending                                           |     |    | √    |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            |     |    | √    |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy  |     |    | √    |
|   | group, paid or unpaid                                                        |     |    |      |
| 11| Stock or stock options                                                       |     |    | √    |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other      |     |    | √    |
|   | services                                                                     |     |    |      |
| 13| Other financial or non-financial interests                                   |     |    | √    |

**Please summarize the above conflict of interest in the following box:**

The authors have no conflicts of interest to declare.

**Please place an “X” next to the following statement to indicate your agreement:**

X ___ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021__

Your Name: __ Wang Ting__

Manuscript Title: __The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.__

Manuscript number (if known): __ATM-21-5648__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _√_ None |
|   | No time limit for this item. | |

Time frame: Since the initial planning of the work

---

Date: ___ November 13, 2021___

Your Name: __ Wang Ting__

Manuscript Title: __The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.__

Manuscript number (if known): __ATM-21-5648__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _√_ None |
|   | No time limit for this item. | |

Time frame: Since the initial planning of the work
|   | Time frame: past 36 months                                                                 |
|---|-------------------------------------------------------------------------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above)                    |
|   | __√__ None                                                                                |
| 3 | Royalties or licenses                                                                      |
|   | __√__ None                                                                                |
| 4 | Consulting fees                                                                           |
|   | __√__ None                                                                                |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or |
|   | educational events                                                                        |
|   | _ √ ___ None                                                                              |
| 6 | Payment for expert testimony                                                              |
|   | __√__ None                                                                                |
| 7 | Support for attending meetings and/or travel                                               |
|   | __√__ None                                                                                |
| 8 | Patents planned, issued or pending                                                        |
|   | __√__ None                                                                                |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                         |
|   | _ √ ___ None                                                                              |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or |
|   | unpaid                                                                                    |
|   | _ √ ___ None                                                                              |
| 11| Stock or stock options                                                                    |
|   | __√__ None                                                                                |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services          |
|   | __√__ None                                                                                |
| 13| Other financial or non-financial interests                                                 |
|   | __√__ None                                                                                |

Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021

Your Name: Wen-Jing Gu

Manuscript Title: The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ATM-21-5648

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | √ None |

Time frame: Since the initial planning of the work

No time limit for this item.
|   | Grants or contracts from any entity (if not indicated in item #1 above). |   |
|---|---|---|
| 2 | __ ✓ __ None |   |

|   | Royalties or licenses |   |
|---|---|---|
| 3 | __ ✓ __ None |   |

|   | Consulting fees |   |
|---|---|---|
| 4 | __ ✓ __ None |   |

|   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |   |
|---|---|---|
| 5 | _ ✓ __ None |   |

|   | Payment for expert testimony |   |
|---|---|---|
| 6 | __ ✓ __ None |   |

|   | Support for attending meetings and/or travel |   |
|---|---|---|
| 7 | __ ✓ __ None |   |

|   | Patents planned, issued or pending |   |
|---|---|---|
| 8 | __ ✓ __ None |   |

|   | Participation on a Data Safety Monitoring Board or Advisory Board |   |
|---|---|---|
| 9 | _ ✓ __ None |   |

|   | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |   |
|---|---|---|
| 10 | _ ✓ __ None |   |

|   | Stock or stock options |   |
|---|---|---|
| 11 | _ ✓ __ None |   |

|   | Receipt of equipment, materials, drugs, medical writing, gifts or other services |   |
|---|---|---|
| 12 | _ ✓ __ None |   |

|   | Other financial or non-financial interests |   |
|---|---|---|
| 13 | _ ✓ __ None |   |

Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __ November 13, 2021 __________________________________________________________________________

Your Name: __ Xin-Xing Zhang _________________________________________________________________

Manuscript Title: _The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma._

Manuscript number (if known): ___ ATM-21-5648 __________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ✓ None |

Time frame: Since the initial planning of the work

No time limit for this item.
|   | Description                                                                 | Yes | No | None |
|---|-----------------------------------------------------------------------------|-----|----|------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).     |     |    | None |
| 3 | Royalties or licenses                                                        |     |    | None |
| 4 | Consulting fees                                                             |     |    | None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,         |     |    | None |
|   | manuscript writing or educational events                                      |     |    | None |
| 6 | Payment for expert testimony                                                 |     |    | None |
| 7 | Support for attending meetings and/or travel                                  |     |    | None |
| 8 | Patents planned, issued or pending                                           |     |    | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            |     |    | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy |     |    | None |
|   | group, paid or unpaid                                                         |     |    | None |
| 11| Stock or stock options                                                       |     |    | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other      |     |    | None |
|   | services                                                                     |     |    | None |
| 13| Other financial or non-financial interests                                    |     |    | None |

Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021 ____________________________

Your Name: __ Yong-Dong Yan ____________________________

Manuscript Title: The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ATM-21-5648 ____________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _√_ None |

Time frame: Since the initial planning of the work
## Time frame: past 36 months

|   | Description                                                                 | Answer | Notes |
|---|----------------------------------------------------------------------------|--------|-------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).    | __✓__ None |       |
| 3 | Royalties or licenses                                                       | __✓__ None |       |
| 4 | Consulting fees                                                             | __✓__ None |       |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,         | _✓_ None |       |
|   | manuscript writing or educational events                                    |        |       |
| 6 | Payment for expert testimony                                                | __✓__ None |       |
| 7 | Support for attending meetings and/or travel                                | __✓__ None |       |
| 8 | Patents planned, issued or pending                                          | __✓__ None |       |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | _✓_ None |       |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy | _✓_ None |       |
|   | group, paid or unpaid                                                       |        |       |
| 11| Stock or stock options                                                      | _✓_ None |       |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other     | _✓_ None |       |
|   | services                                                                     |        |       |
| 13| Other financial or non-financial interests                                  | _✓_ None |       |

**Please summarize the above conflict of interest in the following box:**

The authors have no conflicts of interest to declare.

**Please place an “X” next to the following statement to indicate your agreement:**

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021

Your Name: Wei Ji

Manuscript Title: The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ATM-21-5648

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | √ None                                                                        |

No time limit for this item.

Time frame: Since the initial planning of the work
|   |   |   |
|---|---|---|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above) | √ None |
| 3 | Royalties or licenses | √ None |
| 4 | Consulting fees | √ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | √ None |
| 6 | Payment for expert testimony | √ None |
| 7 | Support for attending meetings and/or travel | √ None |
| 8 | Patents planned, issued or pending | √ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | √ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | √ None |
| 11 | Stock or stock options | √ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | √ None |
| 13 | Other financial or non-financial interests | √ None |

Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ _ November 13, 2021 __________________________________________________________________________

Your Name: ___ Zheng-Rong Chen __________________________________________________________________________

Manuscript Title: ___ The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ___________ ATM-21-5648 __________________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Time frame: Since the initial planning of the work |
|---------------------------------------------------|

| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | √ None |
### Time frame: past 36 months

|   | Grants or contracts from any entity (if not indicated in item #1 above). | __ √ __ None |
|---|------------------------------------------------------------------------|-------------|
| 3 | Royalties or licenses                                                  | __ √ __ None |
| 4 | Consulting fees                                                        | __ √ __ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _ √ __ None |
| 6 | Payment for expert testimony                                           | __ √ __ None |
| 7 | Support for attending meetings and/or travel                            | __ √ __ None |
| 8 | Patents planned, issued or pending                                     | __ √ __ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board      | _ √ ____ None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _ √ ____ None |
|11 | Stock or stock options                                                 | _ √ ____ None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _ √ ____ None |
|13 | Other financial or non-financial interests                              | _ √ ____ None |

#### Please summarize the above conflict of interest in the following box:

The authors have no conflicts of interest to declare.

#### Please place an “X” next to the following statement to indicate your agreement:

_ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ November 13, 2021

Your Name: Can-Hong Zhu

Manuscript Title: The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.

Manuscript number (if known): ATM-21-5648

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|                  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1                | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _√_ None                                                                          |

Time frame: Since the initial planning of the work
### Time frame: past 36 months

|   | Description                                                                 | Answer | Notes |
|---|-----------------------------------------------------------------------------|--------|-------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).    | _✓_ None |       |
| 3 | Royalties or licenses                                                        | _✓_ None |       |
| 4 | Consulting fees                                                             | _✓_ None |       |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _✓_ None |       |
| 6 | Payment for expert testimony                                                | _✓_ None |       |
| 7 | Support for attending meetings and/or travel                                | _✓_ None |       |
| 8 | Patents planned, issued or pending                                          | _✓_ None |       |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | _✓_ None |       |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _✓_ None |       |
| 11| Stock or stock options                                                       | _✓_ None |       |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | _✓_ None |       |
| 13| Other financial or non-financial interests                                   | _✓_ None |       |

**Please summarize the above conflict of interest in the following box:**

The authors have no conflicts of interest to declare.

**Please place an “X” next to the following statement to indicate your agreement:**

_ X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.